These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17266642)

  • 1. Therapeutic prospects for the prevention of neurodegeneration in Huntington's disease and the polyglutamine repeat disorders.
    Kimura Y; Lee WC; Littleton JT
    Mini Rev Med Chem; 2007 Jan; 7(1):99-106. PubMed ID: 17266642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.
    Wright DJ; Renoir T; Gray LJ; Hannan AJ
    Adv Neurobiol; 2017; 15():93-128. PubMed ID: 28674979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin modulates cell death and is protective in Huntington's disease model.
    Chongtham A; Agrawal N
    Sci Rep; 2016 Jan; 6():18736. PubMed ID: 26728250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntingtin aggregation and toxicity in Huntington's disease.
    Bates G
    Lancet; 2003 May; 361(9369):1642-4. PubMed ID: 12747895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.
    Sugaya K
    Subcell Biochem; 2012; 65():353-88. PubMed ID: 23225011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.
    Wanker EE
    Biol Chem; 2000; 381(9-10):937-42. PubMed ID: 11076024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insoluble TATA-binding protein accumulation in Huntington's disease cortex.
    van Roon-Mom WM; Reid SJ; Jones AL; MacDonald ME; Faull RL; Snell RG
    Brain Res Mol Brain Res; 2002 Dec; 109(1-2):1-10. PubMed ID: 12531510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
    Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
    PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
    Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington's disease.
    Sugaya K; Matsubara S
    Mol Neurodegener; 2012 May; 7():20. PubMed ID: 22583646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein aggregation and neurodegeneration: clues from a yeast model of Huntington's disease.
    Bocharova N; Chave-Cox R; Sokolov S; Knorre D; Severin F
    Biochemistry (Mosc); 2009 Feb; 74(2):231-4. PubMed ID: 19267681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
    Li SH; Li XJ
    Trends Genet; 2004 Mar; 20(3):146-54. PubMed ID: 15036808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation.
    Seidel K; Siswanto S; Fredrich M; Bouzrou M; Brunt ER; van Leeuwen FW; Kampinga HH; Korf HW; Rüb U; den Dunnen WF
    Neuropathol Appl Neurobiol; 2016 Feb; 42(2):153-66. PubMed ID: 26095752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
    Truant R; Atwal RS; Burtnik A
    Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.
    Zhang X; Smith DL; Meriin AB; Engemann S; Russel DE; Roark M; Washington SL; Maxwell MM; Marsh JL; Thompson LM; Wanker EE; Young AB; Housman DE; Bates GP; Sherman MY; Kazantsev AG
    Proc Natl Acad Sci U S A; 2005 Jan; 102(3):892-7. PubMed ID: 15642944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable delivery system containing a peptide inhibitor of polyglutamine aggregation: a step toward therapeutic development in Huntington's disease.
    Joshi AS; Thakur AK
    J Pept Sci; 2014 Aug; 20(8):630-9. PubMed ID: 24788406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
    Schipper-Krom S; Juenemann K; Jansen AH; Wiemhoefer A; van den Nieuwendijk R; Smith DL; Hink MA; Bates GP; Overkleeft H; Ovaa H; Reits E
    FEBS Lett; 2014 Jan; 588(1):151-9. PubMed ID: 24291262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
    Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ
    Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.
    Arndt JR; Chaibva M; Legleiter J
    Biomol Concepts; 2015 Mar; 6(1):33-46. PubMed ID: 25741791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Expanding Clinical Universe of Polyglutamine Disease.
    Huang S; Zhu S; Li XJ; Li S
    Neuroscientist; 2019 Oct; 25(5):512-520. PubMed ID: 30614396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.